Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Kafr El Sheikh General Hospital, Egypt.
J Intensive Care Med. 2024 Oct;39(10):1012-1022. doi: 10.1177/08850666241250319. Epub 2024 May 5.
Critically ill patients with sepsis have a high incidence of vitamin D deficiency. Vitamin D promotes the synthesis of human cathelicidin antimicrobial peptide, a precursor of LL-37, which is a part of the innate immune system. This study investigated the effectiveness and safety of the early administration of high-dose enteral vitamin D in comparison with low-dose vitamin D in patients with sepsis requiring mechanical ventilation (MV). Eighty adult patients with sepsis requiring MV with known vitamin D deficiency were randomly assigned to receive either an enteral 50 000 IU (Group I) or 5000 IU (Group II) vitamin D supplementation. Clinical and laboratory parameters were evaluated at baseline and on days 4 and 7 between the study groups. The change in serum procalcitonin (PCT) levels on day 7 was the primary outcome, while the change in serum LL-37 levels on day 7, changes in sequential organ failure assessment (SOFA) score, and clinical pulmonary infection score on day 7, MV duration, and hospital length of stay (LOS) were the secondary outcomes. The (day 7-day 0) change in serum PCT and LL-37 levels and SOFA score were significantly different in Group I ( = .010, < .001, and < .001, respectively). The SOFA score was significantly different on days 4 and 7 in Group I ( < .001 and < .001, respectively). The incidence of early ventilator-associated pneumonia was significantly different between both treatment groups ( = .025). The hospital LOS was shorter in Group I ( < .001). No 25-hydroxyvitamin-D toxicity was observed in either group. Early enteral administration of high-dose vitamin D in critically ill patients with sepsis requiring MV along with standard treatment for sepsis decreased serum procalcitonin levels, increased serum LL-37 levels, and ameliorated illness severity scores.
严重脓毒症患者维生素 D 缺乏发生率较高。维生素 D 可促进人类抗菌肽 cathelicidin 的合成,后者是 LL-37 的前体,属于固有免疫系统的一部分。本研究旨在对比机械通气(MV)严重脓毒症患者早期给予高剂量与低剂量肠内维生素 D 的有效性和安全性。
80 例已知维生素 D 缺乏且需行 MV 的严重脓毒症成年患者随机分为两组,分别给予肠内 50000 IU(I 组)或 5000 IU(II 组)维生素 D 补充。于基线和第 4、7 天评估两组间的临床和实验室参数。第 7 天血清降钙素原(PCT)水平的变化为主要结局,第 7 天血清 LL-37 水平的变化、序贯器官衰竭评估(SOFA)评分的变化、第 7 天临床肺部感染评分、MV 持续时间和住院时间(LOS)为次要结局。
I 组 PCT 和 LL-37 血清水平和 SOFA 评分的(第 7 天-第 0 天)差值均显著(= 0.010,<0.001 和 <0.001),第 4、7 天 SOFA 评分差值显著(均<0.001)。两组治疗组早期呼吸机相关性肺炎的发生率存在显著差异(= 0.025)。I 组的住院 LOS 更短(<0.001)。两组均未观察到 25-羟维生素 D 毒性。
对于严重脓毒症且需行 MV 的患者,在脓毒症标准治疗基础上早期给予高剂量肠内维生素 D 可降低血清 PCT 水平,增加血清 LL-37 水平,并改善疾病严重程度评分。